Polycyclic compound and application thereof
By developing compounds and pharmaceutical compositions with excellent PARP1 inhibitory activity, the problem of dysregulation of DNA damage repair pathways in the prior art has been solved, and the therapeutic effect of BRCA mutation-related cancers has been significantly inhibited.
Patent Information
- Application Number
- CN202410577418.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-12
AI Technical Summary
Existing anti-tumor drugs are difficult to effectively inhibit PARP1 enzyme, resulting in dysregulation of DNA damage repair pathways, and thus unable to effectively treat proliferative diseases such as cancer caused by BRCA mutations.
A compound with excellent PARP1 inhibitory activity is developed to regulate DNA damage repair pathways, and combined with pharmaceutical compositions such as ERK inhibitors, MEK inhibitors, etc., for the treatment of BRCA mutation-related diseases.
It significantly inhibits the activity of PARP1 enzyme, improves pharmacokinetic performance and safety, and can effectively prevent and treat cancers caused by dysregulation of DNA damage repair pathways, especially breast cancer, ovarian cancer caused by BRCA mutations.
Smart Images

Figure CN118930516A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and specifically to a polycyclic compound used for regulating the DNA damage repair pathway mechanism and a preparation method and use thereof, which is mainly used for the treatment or prevention of proliferative diseases (such as cancer), especially for regulating and treating related diseases caused by BRCA mutations. Background Art
[0002] DNA single-strand damage is the most common intrinsic damage, which is repaired via the base excision repair pathway (BER) and the single-strand break repair pathway (SSBR). BER is used for base excision, gap generation and subsequent gap repair; while SSBR only shows a certain effect after the gap is generated. The BER pathway works throughout the entire cell cycle and is an important target for the development of radiotherapy drugs and chemotherapy sensitizers. Different BER processes require different types of DNA polymerases. Poly (ADP-ribose) polymerase (PARP) is involved in the repair of short and long fragments in the BER pathway. Therefore, finding inhibitors of PARP plays an important role in the development of anti-tumor drugs.
[0003] The PARP family has at least 17 members, of which PARP1 accounts for 80% of the total PARP activity. It is not only directly involved in BER, but also in DNA double-strand repair. When PARP1 is inhibited, the base excision repair mechanism is impaired, and the collision of DNA single-strand breaks with the traveling replication fork will be converted into double-strand breaks and then repaired through the homologous recombination pathway; since DNA double-strand breaks are converted into lethal double-strand breaks, leading to cell death, inhibiting PARP1 will produce a synergistic lethal effect. In short, PARP1 inhibitors can effectively inhibit the BER pathway and the DNA double-strand repair pathway, so the development of PARP1 is an important anti-tumor target. Summary of the invention
[0004] The object of the present invention is to provide a compound represented by formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof and a preparation method and application thereof.
[0005] In a first aspect of the present invention, a compound is provided, wherein the compound is a compound represented by formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof,
[0006]
[0007] in,
[0008] Ring A is selected from the following group:
[0009] Ring B is selected from the group consisting of:
[0010] Ring C is selected from the following group:
[0011] X is selected from the group consisting of N, CR1;
[0012] R1 is independently selected from the following substituted or unsubstituted groups: H, halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, wherein the substitution independently refers to substitution by 1, 2, 3 or 4 groups selected from the following group: halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S;
[0013] R2 is independently selected from the following substituted or unsubstituted groups: H, halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, wherein the substitution independently refers to substitution by 1, 2, 3 or 4 groups selected from the following group: halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S;
[0014] R3 is independently selected from the following substituted or unsubstituted groups: H, halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, wherein the substitution independently refers to substitution by 1, 2, 3 or 4 groups selected from the following group: halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S; or different R3 form a 5-7 membered ring with the connected ring B;
[0015] m and n are each independently selected from the following group: 0, 1, 2, 3, 4, 5, 6;
[0016] Ra and Rb are each independently selected from the following group: H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 6-10Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S.
[0017] In another preferred embodiment, R1 is independently selected from the following group: H, halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S;
[0018] Ra and Rb are each independently selected from the following group: H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Halogenated alkyl.
[0019] In another preferred embodiment, R1 is independently selected from the following group: H, halogen, CN, NH2, hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy;
[0020] Ra and Rb are each independently selected from the following group: H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Halogenated alkyl.
[0021] In another preferred embodiment, R1 is independently selected from the following group: H, halogen, NH2, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy;
[0022] Ra and Rb are each independently selected from the following group: H, C 1-6 alkyl.
[0023] In another preferred embodiment, R2 is independently selected from the following group: H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy.
[0024] In another preferred embodiment, R2 is independently selected from the following group: H, halogen, C 1-6 alkyl.
[0025] In another preferred embodiment, R2 is H.
[0026] In another preferred embodiment, R3 is independently selected from the following group: H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy.
[0027] In another preferred embodiment, R3 is independently selected from the following group: H, halogen, C 1-6 alkyl.
[0028] In another preferred embodiment, R3 is H.
[0029] In another preferred embodiment, when different R3s form a 5-7 membered ring with the connected ring B, the 5-7 membered ring is selected from the following group: C 5-7 Cycloalkyl, 4-10 membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, O or S.
[0030] In another preferred embodiment, the compound is selected from the following group:
[0031]
[0032]
[0033] The second aspect of the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a safe and effective amount of one or more compounds described in the first aspect of the present invention.
[0034] In another preferred embodiment, the pharmaceutical composition further comprises a second active ingredient selected from the following group: ERK inhibitors, MEK inhibitors, KRAS inhibitors, BRAF inhibitors, EGFR inhibitors, Wnt inhibitors, and PD-1 inhibitors.
[0035] In another preferred embodiment, the ERK inhibitor is selected from the following group: AZD0364 and Ulixertinib.
[0036] In another preferred embodiment, the MEK inhibitor is selected from the following group: Trametinib, Binimetinib, Selumetinib.
[0037] In another preferred embodiment, the KRAS inhibitor is selected from the following group: AMG510, MTRX849.
[0038] In another preferred embodiment, the BRAF inhibitor is selected from the following group: vemurafenib, dabrafenib, and contrafenib.
[0039] In another preferred embodiment, the EGFR inhibitor is selected from the following group: afatinib, gefitinib, erlotinib, lapatinib, dacomitinib, icotinib, canertinib, sabutinib, naquotinib, pyrotinib, rolactinib, and osimertinib.
[0040] In another preferred embodiment, the Wnt inhibitor is selected from the following group: IWR-1, ETC-159.
[0041] In another preferred embodiment, the PD-1 inhibitor is selected from the following group: nivolumab, pembrolizumab, pidilizumab, cemiplimab, JS-001, SHR-120, BGB-A317, IBI-308, GLS-010, GB-226, STW204, HX008, HLX10, BAT1306, AK105, LZM 009, or biosimilars of the above drugs.
[0042] The third aspect of the present invention provides a use of the compound described in the first aspect of the present invention or the pharmaceutical composition described in the second aspect of the present invention for preparing a drug, wherein the drug is used for a use selected from the group consisting of:
[0043] 1) Used to regulate DNA damage repair pathways;
[0044] 2) for the prevention and / or treatment of proliferative diseases;
[0045] 3) Used to regulate and / or treat diseases caused by BRCA mutations;
[0046] 4) Used to inhibit PARP enzyme activity;
[0047] 5) Used for preventing and / or treating diseases caused by disorders of DNA damage repair pathways.
[0048] In another preferred embodiment, the BRCA mutation is selected from the following group: BRCA1 disorder, BRCA2 disorder.
[0049] In another preferred embodiment, the proliferative disease is a cancer selected from the group consisting of breast cancer, ovarian cancer, melanoma, prostate cancer, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, brain cancer, and endometrial cancer.
[0050] In another preferred embodiment, the related disease caused by the BRCA mutation is a cancer selected from the following group: breast cancer, ovarian cancer, melanoma, prostate cancer, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, and brain cancer.
[0051] In another preferred embodiment, the related disease caused by the disorder of DNA damage repair pathway is a cancer selected from the following group: breast cancer, ovarian cancer, melanoma, prostate cancer, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, and brain cancer.
[0052] In another preferred embodiment, the PARP is PARP1.
[0053] In another preferred embodiment, the proliferative disease is a disease with high expression of PARP1.
[0054] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION
[0055] After long-term and in-depth research, the inventor unexpectedly prepared a compound of formula I having excellent PARP1 inhibitory activity. On this basis, the inventor completed the present invention.
[0056] the term
[0057] In the present invention, unless otherwise specified, the terms used have the general meanings well known to those skilled in the art.
[0058] In the present invention, the term "halogen" refers to F, Cl, Br or I.
[0059] In the present invention, “C 1-6 The term "alkyl" refers to a straight or branched chain alkyl group containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, or the like.
[0060] In the present invention, the term "C 2-6 The term "alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms and containing one double bond, including but not limited to ethenyl, propenyl, butenyl, isobutenyl, pentenyl and hexenyl.
[0061] In the present invention, the term "C2-6 The term "alkynyl" refers to a straight or branched chain alkynyl group having 2 to 6 carbon atoms and containing one triple bond, including but not limited to ethynyl, propynyl, butynyl, isobutynyl, pentynyl and hexynyl.
[0062] In the present invention, the term "C 3-6 The "cycloalkyl" group includes a group selected from the group consisting of: C 3-6 Cycloalkyl, C 3-6 Cycloalkenyl, C 3-6 Cycloalkynyl.
[0063] In the present invention, the term "C 3-6 "Cycloalkyl" refers to a cyclic alkyl group having 3 to 6 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. The term "Cycloalkyl" refers to a cyclic alkyl group having 3 to 6 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. 5-7 "Cycloalkyl" has a similar meaning.
[0064] In the present invention, the term "C 5-8 The term "bridged cyclic group" refers to a cyclic alkyl group having a bridge and 5 to 8 carbon atoms, including but not limited to wait.
[0065] In the present invention, the term "C 1-6 "Alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, isopropoxy and butoxy. Preferably, C 1-4 Alkoxy.
[0066] In the present invention, the term "heterocyclic group" refers to a 4-8 membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, O and S, including (but not limited to) the following groups:
[0067] In the present invention, the term "aromatic ring" or "aryl group" has the same meaning, preferably "C 6-10 The term "C 6-10 The term "aryl" refers to an aromatic ring group having 6 to 10 carbon atoms and containing no heteroatoms in the ring, such as phenyl, naphthyl, etc.
[0068] In the present invention, the term "aromatic heterocycle" or "heteroaryl" has the same meaning and refers to a heteroaromatic group containing one to multiple heteroatoms. For example, "C3-C10 heteroaryl" refers to an aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen and 3 to 10 carbon atoms. Non-limiting examples include: furanyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted.
[0069] In the present invention, the term "halo" means substituted with halogen.
[0070] In the present invention, the term "deuterated" means substituted with deuterium.
[0071] In the present invention, the term "substituted" refers to one or more hydrogen atoms on a specific group being replaced by a specific substituent. The specific substituent is the substituent described above, or the substituent appearing in each embodiment. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable position of the group, and the substituent may be the same or different at each position. It should be understood by those skilled in the art that the combination of substituents contemplated by the present invention is those stable or chemically feasible combinations. The substituents include, for example (but not limited to): halogen, hydroxyl, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclic radical, aryl, heteroaryl, C1-C8 aldehyde, C2-C10 acyl, C2-C10 ester, amino, C1-C6 alkoxy, C1-C10 sulfonyl, etc.
[0072] In the present invention, the term 1-6 refers to 1, 2, 3, 4, 5 or 6. Other similar terms independently have similar meanings. The term "plurality" refers to 2-6, such as 2, 3, 4, 5 or 6.
[0073] It should be understood that when a group is present in multiple different positions of a compound at the same time, its definition at each position is independent of each other and may be the same or different. That is, the term "selected from the following group:" has the same meaning as the term "each independently selected from the following group:".
[0074] Compound
[0075] The present invention provides a compound, which is a compound represented by Formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof.
[0076]
[0077] wherein each group is as defined above.
[0078] In another preferred embodiment, in the compound, any one of ring A, ring B and ring C is independently a corresponding group in the specific compound of the present invention.
[0079] As used herein, the term "pharmaceutically acceptable salt" refers to a salt formed by a compound of the present invention and an acid or base that is suitable for use as a drug. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts is a salt formed by a compound of the present invention and an acid. Suitable acids for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid.
[0080] Another preferred salt is a salt of the compound of the present invention and a base, such as an alkali metal salt (e.g., sodium salt or potassium salt), an alkaline earth metal salt (e.g., magnesium salt or calcium salt), an ammonium salt (e.g., lower alkanolammonium salt and other pharmaceutically acceptable amine salts), for example, methylamine salt, ethylamine salt, propylamine salt, dimethylamine salt, trimethylamine salt, diethylamine salt, triethylamine salt, tert-butylamine salt, ethylenediamine salt, hydroxyethylamine salt, dihydroxyethylamine salt, trihydroxyethylamine salt, and amine salts formed from morpholine, piperazine, and lysine, respectively.
[0081] The term "solvate" refers to a complex formed by the coordination of the compound of the present invention with solvent molecules in a specific ratio. "Hydrate" refers to a complex formed by the coordination of the compound of the present invention with water.
[0082] In addition, the compounds of the present invention also include prodrugs of the compounds shown in Formula I. The term "prodrug" includes a compound that can be biologically active or inactive, and when taken by an appropriate method, it undergoes metabolism or chemical reactions in the human body and is converted into a class of compounds of Formula I, or a salt or solution composed of a compound of Formula I. The prodrug includes (but is not limited to) carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amino compound, carbamate, azo compound, phosphoramide, glucoside, ether, acetal and the like forms of the compound.
[0083] The examples of the present invention specifically describe the preparation methods of the compounds of formula I of the present invention, but these specific methods do not constitute any limitation to the present invention. The compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combinations can be easily carried out by those skilled in the art to which the present invention belongs.
[0084] Typically, the raw materials and reagents used in the process for preparing the compounds of the present invention can be purchased through commercial channels unless otherwise specified.
[0085] Pharmaceutical compositions and methods of administration
[0086] The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compounds.
[0087] Since the compounds of the present invention have excellent anti-tumor activity, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate tumor-related diseases.
[0088] The pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 10-1000 mg of the compound of the present invention per dose. Preferably, the "one dose" is a capsule or tablet.
[0089] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0090] The pharmaceutical composition is in the form of injection, capsule, tablet, pill, powder or granule.
[0091] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administrations include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
[0092] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0093] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0094] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
[0095] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0096] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.
[0097] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0098] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0099] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (such as anti-tumor drugs).
[0100] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.
[0101] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill of a skilled physician.
[0102] Compared with the prior art, the present invention has the following main advantages:
[0103] (1) The compounds of the present invention have significantly excellent PARP1 inhibitory activity;
[0104] (2) The compounds of the present invention have excellent pharmacokinetic properties and safety;
[0105] (3) The compounds of the present invention have excellent blood-brain barrier (BBB) permeability.
[0106] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0107] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0108] Example 1
[0109] The compound synthesized by the present invention:
[0110]
[0111] The synthetic route is as follows:
[0112]
[0113] The experimental process is as follows:
[0114] Synthesis of T04-2
[0115]
[0116] T04-1 (25 g), hydrazine hydrate (75 ml) and ethanol (100 ml) were added to the reaction bottle, and then refluxed at 80 degrees for 16 hours. A white solid precipitated, cooled to room temperature, filtered, washed with ethanol and petroleum ether, and dried to obtain a product which was directly used in the next reaction.
[0117] Synthesis of T04-3
[0118]
[0119] Compound T04-2 (5 g, 1.0 eq) and POCl3 (50 mL) were added to a 100 mL three-necked flask, and reacted at 120 degrees under N2 protection for one hour. The color of the solution changed from white to orange. LCMS showed that most of it was the product, and TLC showed that the raw material had reacted. The reaction was cooled to room temperature, slowly added to ice water, extracted with dichloromethane, repeatedly washed with saturated brine, washed away insoluble matter, concentrated the organic phase, and column chromatography obtained T04-3 (1.45 g).
[0120] Synthesis of T04-4
[0121]
[0122] Compound T04-3 (945 mg, 1.0 eq), AIBN (73 mg, 0.1 eq), (7.33 mg, 2.0 eq) were dissolved in CCl4 (20 mL) and stirred at room temperature at 80 degrees under N2 overnight.
[0123] Post-treatment: the reaction solution was diluted with DCM, filtered, and the filtrate was concentrated to dryness and column chromatography was performed to obtain the crude product T04-4 (1 g).
[0124] Synthesis of T04-5
[0125]
[0126] T04-4 (1 g, 1 eq) and 4-amino-1-tert-butyloxycarbonylpiperidine (824 mg, 1.2 eq) were dissolved in dioxane (20 mL), and DIEA (873 mg, 2 eq) was added to replace N2. The mixture was heated to 60°C and reacted for about 3 hours. LCMS showed that most of the mixture was product.
[0127] Post-treatment: dilute with EA, filter with diatomaceous earth, concentrate the filtrate to dryness, add toluene (6V) and ethanol (6V) respectively, and spin dry, repeat the previous step, add PE, solid precipitates, and filter the solid with the aid of an ultrasonic device to obtain the product T04-5 (1g).
[0128] Synthesis of T04-6
[0129]
[0130] T04-5 (1 g) was dissolved in dichloromethane (5 mL) and 1,4-dioxane hydrochloride (10 ml), N2 was replaced, and the reaction was carried out at room temperature for about 2 h. LCMS showed that most of the product was produced, and TLC showed that the raw material reaction was complete. The reaction solution was spin-dried, and dichloromethane was added and then spin-dried again, and repeated 3 times. The product hydrochloride 1 g was obtained. The hydrochloride was dissolved in a saturated sodium bicarbonate aqueous solution, and then extracted with EA, and the treated T04-6 (345 mg) was obtained after spin-drying.
[0131] Synthesis of T04-7
[0132]
[0133] The treated T04-6 (345 mg, 1 eq), 4,4-difluorocyclohexanone (202.5 mg, 1.2 eq), and glacial acetic acid (7.2 ul, 0.1 eq) were dissolved in methanol (7 mL), N2 was replaced, and the reaction was carried out at room temperature for 30 min. Sodium cyanoborohydride (158 mg, 2 eq) was added and the reaction was carried out at room temperature for about 17 h. LCMS showed that most of it was product, and TLC showed that the reaction of the raw material was complete.
[0134] Post-treatment: extract with water and EA, spin dry and obtain T04-7 (74 mg) by column chromatography.
[0135] Synthesis of T04
[0136]
[0137] T04-7 (74 mg) was dissolved in glacial acetic acid (7.5 mL), the atmosphere was replaced with N2, the temperature was raised to 120°C, and the reaction was carried out for about 17 h.
[0138] Post-treatment: extract with water and EA, spin dry and obtain T04 (29 mg) by column chromatography.
[0139] 1 H NMR(400MHz,Chloroform-d)δ8.67(s,1H),8.04(d,J=7.6Hz,1H),7.76–7.67(m,2H),5.34(s,1H),4 .72(s,2H),3.80(s,1H),3.04(s,2H),2.38(s,3H),2.21(d,J=9.2Hz,4H),2.00(s,5H),1.86(s,6H).
[0140] Referring to the synthesis method of Example 1, the following compound was synthesized:
[0141]
[0142] The biological activity test experimental process is as follows:
[0143] Test Example 1 Cell Antiproliferation Experiment
[0144] Proliferation inhibition assay of PARP1 inhibitor compounds on KURAMOCHI (human ovarian cancer cells), MDA-MB-436 (human breast cancer cells), HCC1806 (human breast squamous carcinoma cells)
[0145] Experimental materials and equipment: HCC1806 was purchased from ATCC, MDA-MB-436 was purchased from Beina Biotechnology, and KURAMOCHI was purchased from Nanjing Kebai Biotechnology Co., Ltd. RPMI-1640 medium (Bio-Channel), DMSO (dimethyl sulfoxide), CCK8 (WST-8) cell analysis kit (Biyuntian), 0.25% EDTA-Tripsin (trypsin digestion solution), 1xPBS (phosphate buffer, pH 7.2), 96-well plate (Corning), fetal bovine serum (FBS), 10,000U / mL penicillin-G / streptomycin, high-speed refrigerated centrifuge (EPPENDORF 5810R), enzyme-linked immunosorbent assay (Tecan Spark).
[0146] Experimental preparation:
[0147] 1. Cell plating
[0148] A) Tumor cells were cultured in RPMI-1640 (containing 10% FBS and 100 U / mL penicillin-G / streptomycin) at 37°C, 5% CO2 and saturated humidity to 80-90% confluence.
[0149] B) Remove the culture medium from the 10 cm culture dish;
[0150] C) Rinse the cells once with 10 ml 1xPBS;
[0151] D) Add 4 ml of 0.25% EDTA-Tripsin and place in a 37°C, 5% CO2 incubator for trypsin digestion for 5 minutes, transfer to a 15 ml centrifuge tube, centrifuge at 200 g for 5 minutes, and discard the supernatant to obtain a cell pellet;
[0152] E) Resuspend in 4 ml DMEM medium, count and adjust to 10,000 cells / ml.
[0153] F) The cell suspension was added to a 96-well plate at a volume of 100 μL per well and cultured overnight in a 37° C., 5% CO 2 incubator.
[0154] 2. Compound treatment
[0155] Compound dilution
[0156] A) Preparation of test compound gradient dilution solutions: Prepare the test compound into a 1 mM stock solution. Then dissolve 1.5 μl of the stock solution in 1.5 ml of DMSO-free culture medium, and then perform 3-fold continuous gradient dilutions with 0.1% DMSO culture medium, for a total of 9 concentrations. The compound concentrations after dilution are as follows:
[0157] 333.33nM, 111.11nM, 37.03nM, 12.35nM, 4.15nM, 1.37nM, 0.46nM, 0.15nM
[0158] B) After thorough mixing, 100 μL of the culture compound solution was taken to replace the culture medium in the cell culture plate, with 4 replicate wells for each concentration;
[0159] C) Transfer the cells to an incubator and incubate for 3 days.
[0160] 3. CCK8 (WST-8) cell analysis
[0161] A) Take out the cell culture plate and add 10 μl of CCK-8 (WST-8) solution to each well in a biosafety cabinet;
[0162] B) Place the cell culture plate back into the incubator and continue incubating for 3 hours;
[0163] C) Select 450 nm wavelength to measure the absorbance value on TECAN enzyme-linked immunosorbent assay instrument.
[0164] 4. Data Analysis
[0165] The cell viability (% Cell Viabi lity) was calculated using the following formula:
[0166] Cell viability (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100
[0167] A (drug added): absorbance of wells with cells, CCK8 solution, and drug solution
[0168] A (blank): absorbance of wells with culture medium and CCK8 solution but no cells
[0169] A(0 drug addition): absorbance of the well with cells, CCK8 solution and no drug solution
[0170] Cell viability: The cell proliferation activity or cytotoxic activity was analyzed by curve fitting using GraphPad Prism 8 software to obtain the IC50 value.
[0171] As shown in Table 1, where A≤100nM; 100nM <B<1μM;1μM≤C≤3μM
[0172] Table 1
[0173]
[0174] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A compound, It is characterized in that The compound is a compound represented by formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof, in, Ring A is selected from the following group: Ring B is selected from the group consisting of: Ring C is selected from the following group: X is selected from the following group: N, CR 1 ; R 1 Each is independently selected from the following groups: substituted or unsubstituted: H, halogen, CN, NH 2 , hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, wherein the substitution independently refers to substitution by 1, 2, 3 or 4 groups selected from the group consisting of halogen, CN, NH 2 , hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S; R 2 Each is independently selected from the following groups: substituted or unsubstituted: H, halogen, CN, NH 2 , hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, wherein the substitution independently refers to substitution by 1, 2, 3 or 4 groups selected from the group consisting of halogen, CN, NH 2 , hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S; R 3 Each is independently selected from the following groups: substituted or unsubstituted: H, halogen, CN, NH 2 , hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S, wherein the substitution independently refers to substitution by 1, 2, 3 or 4 groups selected from the group consisting of halogen, CN, NH 2 , hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S; or different R 3 A 5-7 membered ring is formed between the two rings together with the connected ring B; m and n are each independently selected from the following group: 0, 1, 2, 3, 4, 5, 6; Ra and Rb are each independently selected from the following group: H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Haloalkyl, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S.
2. The compound according to claim 1, It is characterized in that R 1 Each independently selected from the group consisting of H, halogen, CN, NH 2 , hydroxyl, -O-(C=O)-Ra, -(C=O)-O-Ra, -NRa-(C=O)-NRaRb, -O-(C=O)-NRaRb, -NRa-(C=O)-O-Rb, -(C=O)-NRaRb, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, C 6-10 Aryl, 4-10 membered heteroaryl containing 1, 2 or 3 heteroatoms selected from N, O or S; Ra and Rb are each independently selected from the following group: H, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Halogenated alkyl.
3. The compound according to claim 1, It is characterized in that R 2 Each independently selected from the group consisting of H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy.
4. The compound according to claim 1, It is characterized in that R 3 Each independently selected from the group consisting of H, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy.
5. The compound according to claim 1, It is characterized in that The compound is selected from the group consisting of:
6. A pharmaceutical composition, It is characterized in that The invention comprises a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compound according to claim 1.
7. The pharmaceutical composition according to claim 6, It is characterized in that It also contains a second active ingredient selected from the following group: ERK inhibitor, MEK inhibitor, KRAS inhibitor, BRAF inhibitor, EGFR inhibitor, Wnt inhibitor, PD-1 inhibitor.
8. Use of the compound according to claim 1 or the pharmaceutical composition according to claim 6, It is characterized in that For use in the preparation of a medicament for use selected from the group consisting of: 1) Used to regulate DNA damage repair pathways; 2) for the prevention and / or treatment of proliferative diseases; 3) Used to regulate and / or treat diseases caused by BRCA mutations; 4) Used to inhibit PARP enzyme activity; 5) Used for preventing and / or treating diseases caused by disorders of DNA damage repair pathways.
9. The use according to claim 8, It is characterized in that The proliferative disease is a cancer selected from the group consisting of breast cancer, ovarian cancer, melanoma, prostate cancer, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, brain cancer, and endometrial cancer.
10. The use according to claim 8, It is characterized in that The PARP is PARP1.
